Developer docs
API playgroundTry for free, no card

Search company profiles

CEFALY

Full company profile

uuid02mixg2

Namestring
CEFALY
Websiteurl
cefaly.us
Company typeenum
Private
Founded yearint
2016
Descriptiontext

CEFALY is a Wilton, Connecticut–based (per firmographics) privately held medical device company that sells an FDA-cleared, over-the-counter trigeminal nerve stimulation (eTNS) device for the acute treatment and daily prevention of migraine attacks. Its core technology delivers precise electrical pulses to the supraorbital branch of the trigeminal nerve via a self-adhesive forehead electrode, with two protocols: a 60-minute acute session and a 20-minute daily preventive session. Reported clinical outcomes include 79% of patients experiencing significant headache-pain reduction after one hour of acute treatment, 56% reporting resolution of their most bothersome symptom (nausea, vomiting, light/sound sensitivity) within two hours, and 38.1% achieving a 50%+ reduction in migraine days after three months of preventive use, backed by the ACME, TEAM, and PREMICE studies.

The product ecosystem centers on the CEFALY Device (standard OTC eTNS unit) and the CEFALY Connected variant, which pairs via Bluetooth magnetic connection with the CEFALY App on iOS and Android for session tracking and remote control. Recurring revenue is generated through replacement electrode pads sold as a subscription consumable, supplemented by paid one-on-one CEFALY Coaching Services that support onboarding and treatment optimization. The company operates a hybrid go-to-market: direct-to-consumer sales through a Shopify storefront (shop.cefaly.com), a Cefaly Certified provider channel that funnels clinician recommendations, and product-led growth via the connected app ecosystem. Region storefronts are live for the United States, Europe, Canada, and "Other" markets, with English, French, and Spanish localization, though the app and connected services are explicitly not yet available in the EU. Marketing is multi-channel—organic social across Facebook, Instagram, TikTok, YouTube, LinkedIn, and Pinterest, plus affiliate (Awin) and influencer (Grin) programs, and clinical endorsements such as Dr. Michael A. L. Johnson, MD in Neurology. The device is prescription-free and HSA/FSA eligible.

Short descriptiontext

CEFALY sells an FDA-cleared, over-the-counter trigeminal nerve stimulation device for acute migraine relief and daily prevention, distributed direct-to-consumer via e-commerce and a certified clinician network, with recurring electrode subscriptions and coaching services for individual migraine sufferers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWilton, United States
HQ citystring
Wilton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
migraine medical device, trigeminal nerve stimulation, neuromodulation device, headache treatment device, OTC medical device
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neuromodulation Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Hardware Device Sales
TypeHardware Sales
Description

One-time purchase of the CEFALY migraine treatment device sold directly to consumers through e-commerce. Device is prescription-free and available for direct consumer purchase.

cefaly.com
2Consumable Electrode Refills
TypeSubscription Recurring
Description

Replacement electrodes (self-adhesive) sold as subscription or one-time purchase for ongoing device use.

cefaly.com
3Coaching Services
TypeProfessional Services
Description

Paid coaching sessions offered to help customers learn device usage and optimize migraine management.

cefaly.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Marketing or Sales, Supply Chain, Technology or R&D, Operations, Personnel
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CEFALY manufactures and sells an FDA-cleared over-the-counter medical device that uses precise electrical pulses to stimulate the supraorbital branch of the trigeminal nerve through a self-adhesive electrode placed on the forehead. The device supports a 60-minute acute migraine treatment mode and a 20-minute daily prevention mode, and is complemented by a connected Bluetooth version, a companion mobile app, replacement electrode refills, and one-on-one coaching services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 79% of patients saw significant reduction in headache pain after one hour of Acute treatment
+4 more records
Product overview1 text field

CEFALY offers a unified migraine treatment platform centered on its FDA-cleared trigeminal nerve stimulation device. The core product line includes the standard CEFALY Device for acute and preventive migraine treatment, the CEFALY Connected version with Bluetooth connectivity, and the companion CEFALY App for session tracking and device control. The ecosystem is supplemented by electrode accessories (available via subscription) and personalized coaching services. The company operates exclusively in the migraine treatment space, with all products designed to work together as an integrated migraine management solution.

Product and service5 records
1CEFALY Device
CategoryCore Medical Device
Description

FDA-cleared medical device that delivers precise electrical pulses to the trigeminal nerve via a self-adhesive electrode on the forehead to treat acute migraine attacks and prevent future migraines. Available without prescription for direct consumer purchase.

2CEFALY Connected
CategoryConnected Medical Device
Description

Bluetooth-enabled version of the CEFALY device that pairs with the companion mobile app, allowing users to track treatment sessions, control device settings, and access their migraine history through a magnetic auto-aligning connection.

3CEFALY App
CategoryCompanion Software Application
Description

Mobile application for iOS and Android that pairs with the CEFALY Connected device to track migraine patterns, control treatment sessions, and provide coaching support.

4CEFALY Electrodes
CategoryConsumable Accessory
Description

Replacement self-adhesive electrode pads for the CEFALY device, available through a subscription service for convenient replenishment to support continued device use.

5CEFALY Coaching Services
CategoryProfessional Services
Description

One-on-one paid coaching sessions that help users set up the CEFALY device, learn proper usage, and optimize their migraine management protocols.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeGTM or Marketing Partner
Description

Awin affiliate marketing platform used to manage CEFALY's affiliate partnerships for customer acquisition. The company runs an affiliate program to drive sales through third-party marketing partners.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Grin influencer marketing platform used to manage CEFALY's influencer partnerships. The company collaborates with influencers in the migraine/health space to reach target customers.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Maker of Nerivio, a FDA-cleared wearable remote electrical neuromodulation (REN) device worn on the arm for acute and preventive migraine. Direct competitor targeting the same migraine patient population via a non-pharmacologic, prescription-based or OTC-style connected device model.

TypeDirect peer
Description

Develops gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for migraine, cluster headache, and related conditions. Closely comparable as a non-invasive neurostim competitor in the headache/migraine therapeutic area.

TypeDirect peer
Description

Maker of SpringTMS and now SAVI Dual, single-pulse transcranial magnetic stimulation (sTMS) devices prescribed for acute and preventive migraine. Directly competes with CEFALY in non-invasive, device-based migraine therapy with similar clinical positioning.

TypeEmerging player
Description

Dutch startup developing a thin, wearable patch for chronic migraine using bioelectronic neurostimulation. Emerging player pursuing the same preventive migraine use case with a differentiated thin-film form factor.

TypeEmerging player
Description

Developer of Relivion, a wearable non-invasive brain neuromodulation headset for migraine and depression. Comparable as an emerging neuromodulation device aimed at the same headache/migraine clinical segment.

TypeBroad incumbent
Description

Public neuromodulation company commercializing implantable sacral and pudendal nerve stimulation systems. Operates broadly in the neurostimulation space with overlapping core technology (electrical nerve stimulation) but different indications and an implantable, surgical-channel model.

TypeBroad incumbent
Description

Established neuromodulation company marketing an implantable hypoglossal nerve stimulation device for obstructive sleep apnea. Comparable as a public, scaled neurostimulation incumbent with regulatory and clinical infrastructure CEFALY lacks, though targeting different indications.

TypeEmerging player
Description

Developer of Lenire, a bimodal neuromodulation device (transcutaneous electrical and audio stimulation) for tinnitus. Comparable as a non-invasive, consumer-adjacent neuromodulation company building a clinical-evidence-driven, device-plus-consumables business model.

TypeOthers
Description

Sells a wearable cranial electrical stimulation (CES) device for insomnia, anxiety, and depression. Comparable as a non-prescription, direct-to-consumer neurostim device with overlapping go-to-market patterns (DTC, prescription-free consumer electronics style).

TypeOthers
Description

Markets oral CGRP inhibitor Ubrelvy (ubrogepant) and onabotulinumtoxinA (Botox) for chronic migraine. Comparable as a competitor for the same migraine patient pool via a different (pharmacologic) modality, shaping the competitive landscape for CEFALY's addressable market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CEFALY

Neuromodulation Medical Devicescefaly.us

CEFALY sells an FDA-cleared, over-the-counter trigeminal nerve stimulation device for acute migraine relief and daily prevention, distributed direct-to-consumer via e-commerce and a certified clinician network, with recurring electrode subscriptions and coaching services for individual migraine sufferers.

What CEFALY does

CEFALY is a Wilton, Connecticut–based (per firmographics) privately held medical device company that sells an FDA-cleared, over-the-counter trigeminal nerve stimulation (eTNS) device for the acute treatment and daily prevention of migraine attacks. Its core technology delivers precise electrical pulses to the supraorbital branch of the trigeminal nerve via a self-adhesive forehead electrode, with two protocols: a 60-minute acute session and a 20-minute daily preventive session. Reported clinical outcomes include 79% of patients experiencing significant headache-pain reduction after one hour of acute treatment, 56% reporting resolution of their most bothersome symptom (nausea, vomiting, light/sound sensitivity) within two hours, and 38.1% achieving a 50%+ reduction in migraine days after three months of preventive use, backed by the ACME, TEAM, and PREMICE studies.

The product ecosystem centers on the CEFALY Device (standard OTC eTNS unit) and the CEFALY Connected variant, which pairs via Bluetooth magnetic connection with the CEFALY App on iOS and Android for session tracking and remote control. Recurring revenue is generated through replacement electrode pads sold as a subscription consumable, supplemented by paid one-on-one CEFALY Coaching Services that support onboarding and treatment optimization. The company operates a hybrid go-to-market: direct-to-consumer sales through a Shopify storefront (shop.cefaly.com), a Cefaly Certified provider channel that funnels clinician recommendations, and product-led growth via the connected app ecosystem. Region storefronts are live for the United States, Europe, Canada, and "Other" markets, with English, French, and Spanish localization, though the app and connected services are explicitly not yet available in the EU. Marketing is multi-channel—organic social across Facebook, Instagram, TikTok, YouTube, LinkedIn, and Pinterest, plus affiliate (Awin) and influencer (Grin) programs, and clinical endorsements such as Dr. Michael A. L. Johnson, MD in Neurology. The device is prescription-free and HSA/FSA eligible.

CEFALY firmographics

Firmographics
Name
CEFALY
Website
https://cefaly.us
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
CEFALY sells an FDA-cleared, over-the-counter trigeminal nerve stimulation device for acute migraine relief and daily prevention, distributed direct-to-consumer via e-commerce and a certified clinician network, with recurring electrode subscriptions and coaching services for individual migraine sufferers.
Ownership category
akta.pro rank

CEFALY industry classification

Industry
Product category
Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Migraine medical device
  • Trigeminal nerve stimulation
  • Neuromodulation device
  • Headache treatment device
  • OTC medical device

Where CEFALY is headquartered

Location

Headquarters

HQ city
Wilton
HQ country
United States
HQ region
North America

Offices2 records

Markets served

CEFALY business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Marketing or Sales, Supply Chain, Technology or R&D, Operations, Personnel

Revenue model

  1. Hardware Device Sales: One-time purchase of the CEFALY migraine treatment device sold directly to consumers through e-commerce. Device is prescription-free and available for direct consumer purchase.
  2. Consumable Electrode Refills: Replacement electrodes (self-adhesive) sold as subscription or one-time purchase for ongoing device use.
  3. Coaching Services: Paid coaching sessions offered to help customers learn device usage and optimize migraine management.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

CEFALY product offering

Product offering

Core offering

CEFALY manufactures and sells an FDA-cleared over-the-counter medical device that uses precise electrical pulses to stimulate the supraorbital branch of the trigeminal nerve through a self-adhesive electrode placed on the forehead. The device supports a 60-minute acute migraine treatment mode and a 20-minute daily prevention mode, and is complemented by a connected Bluetooth version, a companion mobile app, replacement electrode refills, and one-on-one coaching services.

Product overview

CEFALY offers a unified migraine treatment platform centered on its FDA-cleared trigeminal nerve stimulation device. The core product line includes the standard CEFALY Device for acute and preventive migraine treatment, the CEFALY Connected version with Bluetooth connectivity, and the companion CEFALY App for session tracking and device control. The ecosystem is supplemented by electrode accessories (available via subscription) and personalized coaching services. The company operates exclusively in the migraine treatment space, with all products designed to work together as an integrated migraine management solution.

Differentiator

Problem solved

Functional benefit

Products and services

  • CEFALY Device FDA-cleared medical device that delivers precise electrical pulses to the trigeminal nerve via a self-adhesive electrode on the forehead to treat acute migraine attacks and prevent future migraines. Available without prescription for direct consumer purchase.
  • CEFALY Connected Bluetooth-enabled version of the CEFALY device that pairs with the companion mobile app, allowing users to track treatment sessions, control device settings, and access their migraine history through a magnetic auto-aligning connection.
  • CEFALY App Mobile application for iOS and Android that pairs with the CEFALY Connected device to track migraine patterns, control treatment sessions, and provide coaching support.
  • CEFALY Electrodes Replacement self-adhesive electrode pads for the CEFALY device, available through a subscription service for convenient replenishment to support continued device use.
  • CEFALY Coaching Services One-on-one paid coaching sessions that help users set up the CEFALY device, learn proper usage, and optimize their migraine management protocols.

Quantifiable outcome

  • 79% of patients saw significant reduction in headache pain after one hour of Acute treatment
  • +4 more outcomes

Companies that use CEFALY

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

CEFALY technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CEFALY partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Awin (Affiliate Platform)minorGTM or Marketing PartnerAwin affiliate marketing platform used to manage CEFALY's affiliate partnerships for customer acquisition. The company runs an affiliate program to drive sales through third-party marketing partners.
  • Grin (Influencer Platform)minorGTM or Marketing PartnerGrin influencer marketing platform used to manage CEFALY's influencer partnerships. The company collaborates with influencers in the migraine/health space to reach target customers.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

CEFALY competitors and assessment

Company assessment

Direct peers

  • Theranica Bio-Electronics: Maker of Nerivio, a FDA-cleared wearable remote electrical neuromodulation (REN) device worn on the arm for acute and preventive migraine. Direct competitor targeting the same migraine patient population via a non-pharmacologic, prescription-based or OTC-style connected device model.
  • electroCore: Develops gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for migraine, cluster headache, and related conditions. Closely comparable as a non-invasive neurostim competitor in the headache/migraine therapeutic area.
  • eNeura: Maker of SpringTMS and now SAVI Dual, single-pulse transcranial magnetic stimulation (sTMS) devices prescribed for acute and preventive migraine. Directly competes with CEFALY in non-invasive, device-based migraine therapy with similar clinical positioning.

Emerging players

  • Salvia BioElectronics: Dutch startup developing a thin, wearable patch for chronic migraine using bioelectronic neurostimulation. Emerging player pursuing the same preventive migraine use case with a differentiated thin-film form factor.
  • Neurolief: Developer of Relivion, a wearable non-invasive brain neuromodulation headset for migraine and depression. Comparable as an emerging neuromodulation device aimed at the same headache/migraine clinical segment.
  • Neuromod Devices: Developer of Lenire, a bimodal neuromodulation device (transcutaneous electrical and audio stimulation) for tinnitus. Comparable as a non-invasive, consumer-adjacent neuromodulation company building a clinical-evidence-driven, device-plus-consumables business model.

Broad incumbents

  • Axonics Modulation Technologies: Public neuromodulation company commercializing implantable sacral and pudendal nerve stimulation systems. Operates broadly in the neurostimulation space with overlapping core technology (electrical nerve stimulation) but different indications and an implantable, surgical-channel model.
  • Inspire Medical Systems: Established neuromodulation company marketing an implantable hypoglossal nerve stimulation device for obstructive sleep apnea. Comparable as a public, scaled neurostimulation incumbent with regulatory and clinical infrastructure CEFALY lacks, though targeting different indications.

Others

  • Fisher Wallace (Brainstim Inc.): Sells a wearable cranial electrical stimulation (CES) device for insomnia, anxiety, and depression. Comparable as a non-prescription, direct-to-consumer neurostim device with overlapping go-to-market patterns (DTC, prescription-free consumer electronics style).
  • AbbVie / Allergan (Ubrelvy / Botox): Markets oral CGRP inhibitor Ubrelvy (ubrogepant) and onabotulinumtoxinA (Botox) for chronic migraine. Comparable as a competitor for the same migraine patient pool via a different (pharmacologic) modality, shaping the competitive landscape for CEFALY's addressable market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

CEFALY social profiles

Digital presence

CEFALY compliance and trust

Trust signal

Compliance1 record

CEFALY financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CEFALY leadership team

Management profile

Number of profiles

CEFALY funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CEFALY M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CEFALY

What does CEFALY do?

CEFALY manufactures and sells an FDA-cleared over-the-counter medical device that uses precise electrical pulses to stimulate the supraorbital branch of the trigeminal nerve through a self-adhesive electrode placed on the forehead. The device supports a 60-minute acute migraine treatment mode and a 20-minute daily prevention mode, and is complemented by a connected Bluetooth version, a companion mobile app, replacement electrode refills, and one-on-one coaching services.

When was CEFALY founded?

CEFALY was founded in 2016. It employs 11 to 50 people.

Where is CEFALY based?

CEFALY is headquartered in Wilton, United States, in the North America region.

How does CEFALY make money?

Three revenue lines are on record. Hardware Device Sales are the primary driver. The others are consumable Electrode Refills and coaching Services.

Who are CEFALY's main competitors?

Direct peers on record are Theranica Bio-Electronics, electroCore and eNeura. Emerging players are Salvia BioElectronics, Neurolief and Neuromod Devices. Broad incumbents are Axonics Modulation Technologies and Inspire Medical Systems. Others are Fisher Wallace (Brainstim Inc.) and AbbVie / Allergan (Ubrelvy / Botox).

Does CEFALY have an API?

No public API is recorded for CEFALY.

What industry is CEFALY in?

CEFALY's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals